Advanced Oncotherapy (AVO) strengthens its board – Daily Telegraph
From Daily Telegraph – StockMarket Wire Advanced Oncotherapy has appointed Dr Nick Plowman as a non-executive director with immediate effect. Plowman is senior clinical oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children at Great Ormond Street in London. Executive chairman Michael Sinclair said: “Dr Plowman has been a welcome source of expert […]
Advanced Oncotherapy (AVO) – Appoints Dr Nick Plowman as Non-Executive Director
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”) and the Hospital for Sick Children at Great Ormond Street (“GOSH”) in London, as a Non-Executive Director with immediate effect. Dr Nick Plowman is the UK’s […]
Advanced Oncotherapy (AVO) – Appointment of Non-Executive Directors
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Professor Steve Myers OBE and Mr Hans von Celsing as Non-Executive Directors with immediate effect. In addition, Mr von Celsing will become Senior Independent Non-Executive Director. Professor Myers’ appointment follows the announcement of the Company’s intention to […]
Advanced Oncotherapy (AVO) – Directorate Change
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Lord David Evans has stepped down from the Board with immediate effect. In addition, the board of directors of Advanced Oncotherapy intends to appoint Professor Stephen Myers as member of the Board. A further announcement in relation to the […]
Advanced Oncotherapy (AVO) – Directorate change
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Nicolas Serandour, Chief Operating Officer and Chief Financial Officer, will become Chief Executive Officer with immediate effect. Michael Sinclair, currently Chief Executive Officer and Executive Chairman, will retain his role as Executive Chairman. Commenting, Dr. Michael Sinclair, Executive Chairman of […]
Advanced Oncotherapy (AVO) – Harley Street planning permission granted
Harley Street planning permission granted Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at a meeting held yesterday at Westminster City Council, planning permission for the Harley Street site was granted. Commenting, Dr. Michael Sinclair, Executive Chairman and CEO of Advanced Oncotherapy, said: “The Harley Street Proton […]
Advanced Oncotherapy (AVO) – Result of AGM and share consolidation
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed. Share Consolidation Following the passing of the share consolidation resolution, every 25 existing ordinary shares of 1 penny each (“Existing Ordinary Shares”) that are in issue […]
Advanced Oncotherapy (AVO) – AGM Presentation
Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, will hold its Annual General Meeting at 12.00 noon at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD on Thursday, 30 June 2016. The Company will provide shareholders with a short presentation on its development so far and […]
Advanced Oncotherapy (AVO) – Final Results for the year ended 31 December 2015
Advanced Oncotherapy (AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2015, a year of good progress in the development of the Company’s LIGHT system. Highlights: Oversubscribed placing to raise £20 million (net) to develop and install first LIGHT system Sale of two […]
Advanced Oncotherapy (AVO) secures of £24m financing for Harley Street
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support the Company’s provision of vendor financing for the […]